FUNDAMENTALS · Fundamentals · US Healthcare

Atara Biotherapeutics (ATRA) Fundamentals 2026 — Revenue Analysis | SniperIQ

Atara Biotherapeutics (ATRA) is a US-listed Healthcare company in Biotechnology with a market capitalization of $75M, trading at $8.34 on the NASDAQ. This SniperIQ fundamentals page covers Atara Biotherapeutics's valuation, profitability (net margin -40.9%), revenue (

21M in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.

Market Cap$75M
Net Margin-40.9%
Revenue (FY25)
21M

Full research coverage

  • 8-Quarter Revenue & Margin Trend
  • Debt Maturity & Coverage
  • Peer Valuation Comparison
  • Free Cash Flow & Owner Earnings
  • AI Signal + Institutional Flow
  • DCF Valuation Model

Frequently Asked Questions

What is Atara Biotherapeutics's market cap?

Atara Biotherapeutics (ATRA) has a market capitalization of approximately $75M, trading at $8.34 on the NASDAQ. Market cap moves with the live share price.

How profitable is Atara Biotherapeutics?

Atara Biotherapeutics runs a net profit margin of -40.9%, a gross margin of 96.1%, and an operating margin of -27.3%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.

How much revenue does Atara Biotherapeutics generate?

Atara Biotherapeutics reported revenue of

21M for fiscal year 2025, with net income of
3M and earnings per share (EPS) of 2.61. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.

Does Atara Biotherapeutics pay a dividend?

Atara Biotherapeutics does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.

Is Atara Biotherapeutics financially healthy?

Atara Biotherapeutics carries a debt-to-equity ratio of -0.27x and a current ratio of 2.16x, with a market beta of 0.09. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.

Is Atara Biotherapeutics a good stock to buy in 2026?

SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Atara Biotherapeutics (ATRA) the key facts are: market cap $75M, revenue

21M, 52-week range 3.92-19.145. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.

Track Atara Biotherapeutics's full fundamentals live

Get Atara Biotherapeutics's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.